Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Beovu. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for brolucizumab-dbll (sold as Beovu), first approved Oct 7, 2019, with 1 new use approved and 0 published complete response letters.
First approved: Oct 7, 2019
Applications: 1
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $10.4M
First approved in the EU: Feb 13, 2020
First approved in Japan: Mar 25, 2020
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Beovu
Part B
$10.2M
-25%
1,113
Beovu
Part D
$148K
-53%
17
Approvals in the EU (EMA)
First approved in the EU 4 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
First approved in Japan 6 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
BeovuA drug with a new indication and a new dosage for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization… · Novartis Pharma K.K. · Nov 20, 2025 · Review report
Beovu kitA drug with a new indication and a new dosage for the treatment of diabetic macular edema. · Novartis Pharma K.K. · Jun 20, 2022
Beovu, new ingredientA drug with a new active ingredient indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization. · Novartis Pharma K.K. · Mar 25, 2020
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA